Literature DB >> 19289651

Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli.

Juan Carlos Q Velez1, Kevin J Ryan, Caroline E Harbeson, Alison M Bland, Milos N Budisavljevic, John M Arthur, Wayne R Fitzgibbon, John R Raymond, Michael G Janech.   

Abstract

Intraglomerular renin-angiotensin system enzyme activities have been examined previously using glomerular lysates and immune-based assays. However, preparation of glomerular extracts compromises the integrity of their anatomic architecture. In addition, antibody-based assays focus on angiotensin (Ang) II detection, ignoring the generation of other Ang I-derived metabolites, some of which may cross-react with Ang II. Therefore, our aim was to examine the metabolism of Ang I in freshly isolated intact glomeruli using matrix-assisted laser desorption ionization time of flight mass spectrometry as an analytic method. Glomeruli from male Sprague-Dawley rats were isolated by sieving and incubated in Krebs buffer in the presence of 1 micromol/L of Ang I for 15 to 90 minutes, with or without various peptidase inhibitors. Peptide sequences were confirmed by matrix-assisted laser desorption ionization time of flight tandem mass spectrometry or linear-trap-quadrupole mass spectrometry. Peaks were quantified using customized valine-(13)C(.15)N-labeled peptides as standards. The most prominent peaks resulting from Ang I cleavage were 899 and 1181 m/z, corresponding with Ang (1-7) and Ang (2-10), respectively. Smaller peaks for Ang II, Ang (1-9), and Ang (3-10) also were detected. The disappearance of Ang I was significantly reduced during inhibition of aminopeptidase A or neprilysin. In contrast, captopril did not alter Ang I degradation. Furthermore, during simultaneous inhibition of aminopeptidase A and neprilysin, the disappearance of Ang I was markedly attenuated compared with all of the other conditions. These results suggest that there is prominent intraglomerular conversion of Ang I to Ang (2-10) and Ang (1-7), mediated by aminopeptidase A and neprilysin, respectively. Formation of these alternative Ang peptides may be critical to counterbalance the local actions of Ang II. Enhancement of these enzymatic activities may constitute potential therapeutic targets for Ang II-mediated glomerular diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289651      PMCID: PMC2706530          DOI: 10.1161/HYPERTENSIONAHA.109.128819

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

1.  Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles.

Authors:  YiLin Ren; Jeffrey L Garvin; Oscar A Carretero
Journal:  Hypertension       Date:  2002-03-01       Impact factor: 10.190

2.  Structure-activity and structure-binding studies of des-Asp(1)-angiotensin I analogues on the rabbit pulmonary artery.

Authors:  Woei-Shin Chen; Meng-Kwoon Sim; Mei-Lin Go
Journal:  Regul Pept       Date:  2002-06-15

3.  Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats.

Authors:  Akira Nishiyama; Dale M Seth; L Gabriel Navar
Journal:  Hypertension       Date:  2002-01       Impact factor: 10.190

4.  Effects of des-aspartate-angiotensin I on angiotensin II-induced incorporation of phenylalanine and thymidine in cultured rat cardiomyocytes and aortic smooth muscle cells.

Authors:  L Min; M K Sim; X G Xu
Journal:  Regul Pept       Date:  2000-11-24

5.  Neutral endopeptidase expression in mesangial cells.

Authors:  Fabiana Ebihara; Giovana Seno Di Marco; Maria Aparecida Juliano; Dulce Elena Casarini
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2003-12       Impact factor: 1.636

6.  ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells.

Authors:  Priscila C Cristovam; Carine P Arnoni; Maria Claudina C de Andrade; Dulce E Casarini; Luciana G Pereira; Nestor Schor; Mirian A Boim
Journal:  Exp Biol Med (Maywood)       Date:  2008-05-14

7.  Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.

Authors:  Xiao R Huang; Wei Y Chen; Luan D Truong; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

8.  Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas.

Authors:  Robson A S Santos; Ana C Simoes e Silva; Christine Maric; Denise M R Silva; Raquel Pillar Machado; Insa de Buhr; Silvia Heringer-Walther; Sergio Veloso B Pinheiro; Myriam Teresa Lopes; Michael Bader; Elizabeth P Mendes; Virgina Soares Lemos; Maria Jose Campagnole-Santos; Heinz-Peter Schultheiss; Robert Speth; Thomas Walther
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 11.205

9.  A pitfall of glomerular sieving: profibrotic and matrix proteins derive from the Bowman's capsule and not the glomerular tuft in rats with renovascular hypertension.

Authors:  O M Steinmetz; U Panzer; S Fehr; C Meyer-Schwesinger; R A K Stahl; U O Wenzel
Journal:  Nephrol Dial Transplant       Date:  2007-07-19       Impact factor: 5.992

10.  Localization of carboxypeptidase A-like enzyme in rat kidney.

Authors:  Rajko Igić; Sandra Garber; Marin Sekosan; Renata A Urbanska; Rahim Behnia
Journal:  Peptides       Date:  2003-08       Impact factor: 3.750

View more
  27 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Authors:  Minghao Ye; Jan Wysocki; Francisco R Gonzalez-Pacheco; Mahmoud Salem; Karla Evora; Laura Garcia-Halpin; Marko Poglitsch; Manfred Schuster; Daniel Batlle
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

3.  Unraveling the glomerular RAS: one peptidase at a time.

Authors:  Lisa M Harrison-Bernard; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-09

4.  Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro.

Authors:  Julie A D Van; Sergi Clotet-Freixas; Joyce Zhou; Ihor Batruch; Chunxiang Sun; Michael Glogauer; Luca Rampoldi; Yesmino Elia; Farid H Mahmud; Etienne Sochett; Eleftherios P Diamandis; James W Scholey; Ana Konvalinka
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

Review 5.  The renin-angiotensin system and prevention of age-related functional decline: where are we now?

Authors:  Corey B Simon; Brittany Lee-McMullen; Dane Phelan; Janine Gilkes; Christy S Carter; Thomas W Buford
Journal:  Age (Dordr)       Date:  2015-02-09

6.  A study of the properties of Gaussian mixture model for stable isotope standard quantification in MALDI-TOF MS.

Authors:  John Christian G Spainhour; Michael G Janech; Viswanathan Ramakrishnan
Journal:  Commun Stat Simul Comput       Date:  2018-01-30       Impact factor: 1.118

Review 7.  The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.

Authors:  Carlos M Ferrario; Jasmina Varagic
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

8.  Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.

Authors:  Jan Wysocki; Minghao Ye; Daniel Batlle
Journal:  Am J Hypertens       Date:  2015-05-11       Impact factor: 2.689

Review 9.  Is the renin-angiotensin system actually hypertensive?

Authors:  Etienne Bérard; Olivier Niel; Amandine Rubio
Journal:  Pediatr Nephrol       Date:  2013-06-06       Impact factor: 3.714

10.  Network modeling reveals steps in angiotensin peptide processing.

Authors:  John H Schwacke; John Christian G Spainhour; Jessalyn L Ierardi; Jose M Chaves; John M Arthur; Michael G Janech; Juan Carlos Q Velez
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.